European Opportunities Trust Reports Challenging Year, Announces Fee Cut and Tender Offer

A Year of Headwinds and Course Correction

European Opportunities Trust (EOT) has just rolled out its annual report card for the year ending May 2025, and it’s fair to say the numbers make for sobering reading. While European equities broadly enjoyed an upswing, this particular trust found itself swimming against the tide. Let’s unpack the details and see how the board and manager are responding.

The Raw Numbers: Underperformance, But a Glimmer of Hope

The headline figures tell a clear story of a tough year:

• Net Asset Value (NAV) Total Return: -3.7%
• Share Price Total Return: -0.9%
• Benchmark (MSCI Europe GBP TR): +8.0%

That’s a significant underperformance gap. Chair Matthew Dobbs didn’t sugarcoat it, acknowledging the “disappointment” for shareholders, particularly as the trust’s three, five, and ten-year returns also lag the benchmark.

The silver lining? A notable bounce since the year-end. As of 31st July, the NAV had jumped 5.9% to 1,026p, handily outpacing the benchmark’s 1.5% gain. Is this the start of a turnaround, or just a blip? Time will tell.

Keeping the Lights On: Dividend & Discount Dynamics

In line with its capital growth focus, EOT kept its annual dividend steady at 2.0p per share. Crucially, this was funded from revenue reserves – a key advantage of the investment trust structure allowing income smoothing.

The discount (the gap between the share price and the underlying NAV) narrowed to 7.5% at year-end (down from 10.2%). While still wider than the AIC Europe sector average of 5.4%, active buybacks (£24.5m worth during the year) helped manage volatility. The board aims to keep it in single digits.

Shareholder Concessions: The Fee Cut & Tender Offers

Recognising the performance struggles, the Board has taken concrete steps:

• Fee Reduction: A significant overhaul kicks in on 1st October 2025. The old tiered structure (starting at 0.80%) is replaced by a much lower one: 0.65% on the first £400m, 0.60% on the next £200m, and 0.55% above £600m. This is a material cost saving for shareholders.
• Tender Offer (Done): A 25% tender offer was completed in June 2025, allowing shareholders an exit near NAV and reducing assets under management to £463m.
• Tender Offer (Potential): A further 25% tender is on the table, conditional on performance. If EOT fails to match or beat its benchmark over the three years ending May 2026, it will be triggered after the 2026 AGM. Currently, the trust is behind.

These are clear signals the Board is listening and aligning interests with shareholders facing persistent underperformance.

Managerial Shake-Up: The River Global Merger

Adding another layer of intrigue, investment manager Devon Equity Management announced a proposed merger with River Global PLC. The Board has given cautious approval, citing potential benefits:

• River’s commitment to the investment trust sector.
• Expanded portfolio management and analyst resources.
• Enhanced marketing and distribution muscle.

Key reassurances were given: Devon’s key staff remain committed, and the core investment philosophy and process stay intact. Crucially, the new fee structure is locked in regardless of the merger outcome. Regulatory approval (FCA) is pending.

Inside the Engine Room: Portfolio Performance & Strategy

Manager Alexander Darwall’s review highlighted the trust’s focus on European companies with global reach, avoiding mainstream financials – a sector that performed well and contributed to the relative lag. Key portfolio themes are productivity (tech/healthcare), disruption (Wise, Ryanair), defence, and electrification.

Top Contributors (Saving Grace):

• Deutsche Börse (7.3% weight): Thrived on market turmoil (+54.6%).
• RELX (7.7% weight): Continued growth, boosted by AI (+18.8%).
• Gaztransport & Technigaz (3.7% weight): Benefited from LNG demand (+26.7%).
• Thales (1.6% weight) & Genus (5.2% weight): Defence spending and FDA gene-editing approval drove gains.

Top Detractors (Drag Anchors):

• Novo Nordisk (10.4% weight): The big one. Fears over competition in obesity drugs crushed the share price (-50.8%). Darwall remains bullish on its long-term pipeline and scale.
• Edenred (4.7% weight): Regulatory concerns spooked investors (-35.6%).
• Worldline (1.2% weight): Sold after admitting faulty analysis (-58.3%).
• Dassault Systèmes (7.3% weight) & Oxford Instruments (2.4% weight): Hit by auto sector pauses (tariff fears) and tariff concerns respectively.

Portfolio activity was relatively muted (20% turnover). New additions included Universal Music Group (music catalogues), Exosens (defence/night vision), Wise (payments), and VAT Group (semiconductors). Darktrace was sold following its takeover.

Gazing Ahead: Trump, Turmoil & Transformation

The outlook is framed by two shadows: Trump-era tariff policies and geopolitical conflicts. However, the manager sees reasons for cautious optimism:

• European equities look relatively attractive vs. the US, partly due to “Trump turmoil”.
• Lower oil/gas prices benefit Europe.
• Germany’s fiscal strength enables massive increases in defence spending (targeting 3.5% GDP by 2029) and a €500bn infrastructure fund – a significant stimulus.
• Portfolio companies like Genus, Camurus, Novo Nordisk (despite setbacks), Infineon, and Dassault report breakthrough developments promising future profits.

The core belief remains: EOT’s “special” companies, with global demand, pricing power, and strong balance sheets, are positioned to thrive long-term.

The Bottom Line: Repairs Underway, But the Jury’s Out

European Opportunities Trust faced a bruising year. The Board hasn’t stood still – slashing fees, executing a tender, and setting up a potential future one tied to performance. The Devon/River merger adds another variable. Manager Darwall maintains conviction in his high-conviction, global-Europe strategy, pointing to recent green shoots and transformative developments in the portfolio.

The elephant in the room remains the looming 2026 continuation vote and the conditional tender offer. For existing shareholders, the fee cut and discount management are tangible positives. For potential investors, the recent performance uptick and strategic shifts warrant close watching, but the track record demands caution. One thing’s certain: all eyes will be on whether the promised longer-term vindication of the strategy starts materialising well before the 2026 AGM showdown.